Home » Medical Devices » Belgium Cardiovascular Devices Market

Belgium Cardiovascular Devices Market

Belgium Cardiovascular Devices Market By Product (Diagnostic & Monitoring Devices, Surgical Devices); By End User (Hospitals & Clinics, Diagnostic Laboratories, Ambulatory Surgical Centers, Others); By Diagnostic & Monitoring Devices Type (ECG, Implantable Cardiac Monitors, Holter Monitors, Mobile Cardiac Telemetry, MRI, Others); By Surgical Devices Type (Cardiac Resynchronization Therapy (CRT), Implantable Cardioverter Defibrillators (ICDs), Pacemakers, Coronary Stents, Catheters) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Summary
Table Of Content

REPORT ATTRIBUTE	DETAILS
Historical Period	2020-2023
Base Year	2024
Forecast Period	2025-2032
Belgium Cardiovascular Devices Market Size 2024	USD449.08 million
Belgium Cardiovascular Devices Market, CGR	5.2%
Belgium Cardiovascular Devices Market Size 2032	USD706.83 million

Market Overview

The Belgium Cardiovascular Devices Market is projected to grow from USD449.08 million in 2024 to an estimated USD706.83 million by 2032, with a compound annual growth rate (CAGR) of 5.2% from 2025 to 2032. This growth reflects the rising burden of cardiovascular diseases (CVDs), increasing healthcare expenditure, and the growing adoption of advanced medical technologies across the country.

Key drivers fueling market growth include the rising incidence of coronary artery diseases and heart failure, along with technological advancements in minimally invasive procedures. Trends such as the integration of artificial intelligence in cardiac diagnostics, increased use of telecardiology, and the development of portable and wearable cardiac monitoring devices are transforming patient care. Moreover, supportive regulatory frameworks and favorable reimbursement policies are encouraging hospitals and clinics to adopt innovative cardiovascular technologies.

Geographically, Belgium’s cardiovascular device market sees strong activity in urban regions like Brussels, Antwerp, and Ghent, where leading healthcare institutions are concentrated. Key players operating in the Belgium market include Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, GE HealthCare, Siemens Healthineers, and Philips Healthcare. These companies are continuously innovating through product launches, collaborations, and R&D investments to maintain a competitive edge and expand their footprint across Belgium’s growing cardiovascular segment.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research!

Download Sample

Market Insights

The Belgium Cardiovascular Devices Market is projected to grow from USD449.08 million in 2024 to USD706.83 million by 2032, registering a CAGR of 5.2% from 2025 to 2032.
The global cardiovascular devices market is projected to grow from USD 72,115.60 million in 2024 to USD 133,700.94 million by 2032, with a CAGR of 7.1% from 2025 to 2032, driven by increasing cardiovascular diseases and advancements in medical technology.
Aging population and increasing cases of heart disease, obesity, and diabetes are driving consistent demand for advanced cardiovascular treatments.
Minimally invasive procedures, AI-integrated diagnostics, and wearable cardiac monitors are reshaping the market and improving patient care.
Favorable reimbursement policies and alignment with EU medical device regulations are accelerating the adoption of innovative cardiovascular technologies.
High prices of advanced devices and delayed reimbursement for new technologies pose challenges to broader access and adoption.
Flanders leads with 48% market share, followed by Wallonia at 32%, and Brussels at 20%, with urban centers driving innovation and infrastructure investment.
Major companies such as Medtronic, Abbott, Boston Scientific, and GE HealthCare dominate the market through product innovation and strategic partnerships.

Report Scope

This report segments the Belgium Cardiovascular Devices Market as follows:

Market Drivers

Rising Prevalence of Cardiovascular Diseases (CVDs)

One of the primary factors driving the growth of the Belgium Cardiovascular Devices Market is the increasing prevalence of cardiovascular diseases across the country. Belgium, like many Western European nations, is experiencing a steady rise in cases of coronary artery disease, arrhythmia, heart failure, and stroke. For instance, according to the World Heart Observatory, Belgium recorded 33,627 deaths due to cardiovascular diseases in 2019. The age-standardized cardiovascular disease mortality rate was 119 per 100,000 population, while the incidence rate stood at 547 per 100,000 population. Additionally, hypertension remains a significant concern, with 22.4% of men and 12.6% of women in Belgium affected. As a result, there is a growing demand for both diagnostic and therapeutic cardiovascular devices, including pacemakers, implantable cardioverter defibrillators (ICDs), stents, catheters, and echocardiography systems. Hospitals and cardiology clinics are increasingly adopting these devices to improve patient outcomes and reduce the burden of recurrent hospitalizations. This growing patient pool is expected to sustain long-term demand for innovative and effective cardiovascular technologies.

Technological Advancements and Product Innovation

Technological innovation is playing a crucial role in accelerating the development and adoption of advanced cardiovascular devices in Belgium. The industry has seen a significant evolution in terms of device design, functionality, and integration of digital health technologies. Belgium has been actively involved in cardiovascular device innovation. Research in European medical institutions has led to advancements in percutaneous coronary intervention, cardiac imaging, transcatheter heart valve implantation, and device therapy for cardiac arrhythmias and heart failure. Additionally, wearable devices and AI-driven diagnostics are reshaping patient-centric healthcare, enabling real-time monitoring and personalized treatment strategies. Minimally invasive procedures enabled by image-guided catheterization systems and 3D-printed cardiac models have improved procedural accuracy while reducing patient recovery time. Similarly, next-generation drug-eluting stents, leadless pacemakers, and transcatheter aortic valve replacement (TAVR) systems are gaining traction among Belgian healthcare providers for their superior clinical outcomes and reduced risk profiles. Furthermore, the integration of artificial intelligence and machine learning in cardiovascular diagnostics—particularly in electrocardiography (ECG) and cardiac imaging—has enhanced the precision of disease detection and risk stratification. Wearable and portable cardiac monitors, such as smart ECG patches and mobile cardiac telemetry, are also becoming increasingly popular in outpatient care. These innovations, supported by a robust regulatory environment and active R&D initiatives from European medical institutions, are fueling market expansion and improving the overall standard of cardiovascular care in Belgium.

Supportive Government Policies and Healthcare Infrastructure

Belgium’s well-structured and publicly funded healthcare system plays a significant role in supporting the cardiovascular devices market. The country boasts high standards of medical infrastructure, widespread availability of specialized cardiovascular care, and favorable reimbursement frameworks for essential medical devices. For instance, the National Institute for Health and Disability Insurance (INAMI/RIZIV) provides comprehensive coverage for a range of cardiovascular diagnostics and surgical interventions, enabling greater access to advanced technologies across both public and private healthcare settings. Additionally, Belgium has been active in adopting European Union (EU) medical device regulations that prioritize patient safety, quality assurance, and clinical evaluation. These regulatory practices, in combination with initiatives to improve early diagnosis and prevention of chronic diseases, have created a conducive environment for medical device manufacturers and suppliers. Investments in hospital modernization programs, health IT infrastructure, and collaborative public-private healthcare projects are further boosting the demand for high-performance cardiovascular solutions.

Increasing Geriatric Population and Preventive Healthcare Trends

Demographic shifts in Belgium are leading to a rapidly aging population, which inherently increases the incidence of cardiovascular conditions that require device-based intervention. According to Statistics Belgium, the proportion of individuals aged 65 years and older is projected to rise significantly over the coming decades, thereby exerting upward pressure on the country’s healthcare system. This aging trend directly correlates with a higher demand for devices that manage age-associated cardiac disorders, including arrhythmias, valve disorders, and heart failure. Moreover, the healthcare sector in Belgium is witnessing a strong push toward preventive and personalized care. Public health campaigns promoting early detection of cardiovascular risk factors, such as high blood pressure and high cholesterol, are leading to greater use of non-invasive monitoring tools and diagnostic imaging systems. Preventive screenings and telecardiology services are becoming increasingly popular among the elderly population, who prefer home-based or remote consultations for chronic disease management. This shift toward prevention and long-term monitoring is propelling demand for ambulatory cardiac monitoring devices, wearable technologies, and AI-enabled remote diagnostics, further reinforcing the growth trajectory of the cardiovascular devices market in Belgium.

Market Trends

Surge in Demand for Minimally Invasive Cardiovascular Procedures

The Belgium cardiovascular devices market is witnessing a significant shift toward minimally invasive procedures as both patients and healthcare providers prioritize quicker recovery times, lower complication rates, and reduced hospital stays. Techniques such as transcatheter aortic valve replacement (TAVR), balloon angioplasty, and percutaneous coronary interventions (PCI) are increasingly being preferred over traditional open-heart surgeries. These procedures rely heavily on technologically advanced devices such as guidewires, catheters, vascular closure devices, and stent systems. Belgian hospitals, particularly university and tertiary care centers, are rapidly adopting such innovations to enhance surgical precision and patient comfort. For instance, robotic-assisted cardiac surgery has been successfully implemented in several Belgian hospitals, including University Hospital Leuven and Cliniques Universitaires Saint-Luc in Brussels, improving procedural accuracy and patient outcomes. The government’s investment in upgrading cath labs and expanding interventional cardiology departments further supports this trend. Additionally, continuous training programs and skill development initiatives are equipping cardiologists with the expertise needed for complex catheter-based interventions. As patient awareness grows and the geriatric population expands, the demand for less invasive and more cost-effective cardiac procedures is expected to accelerate. This trend not only enhances clinical outcomes but also fuels market growth by increasing the adoption of next-generation cardiovascular devices across Belgium’s healthcare ecosystem. For instance, Ziekenhuis Oost Limburg in Genk has reported a steady increase in minimally invasive coronary artery bypass grafting procedures, reflecting the growing preference for advanced surgical techniques.

Integration of Artificial Intelligence and Digital Health Technologies

The integration of artificial intelligence (AI), machine learning, and digital health platforms is transforming the cardiovascular devices landscape in Belgium. Hospitals and medical institutions are increasingly utilizing AI-enabled diagnostic tools, such as advanced ECG analysis software and automated cardiac imaging systems, to improve diagnostic speed and accuracy. Machine learning algorithms are being applied to large-scale patient data to predict cardiovascular events, stratify patient risks, and optimize treatment planning. Additionally, digital health tools such as wearable heart monitors, mobile health apps, and cloud-based telemetry systems are being adopted for remote patient monitoring and post-operative care. This digital shift enhances real-time data sharing between patients and healthcare providers, facilitating faster clinical decisions and personalized treatment pathways. Belgium’s strong IT infrastructure, coupled with EU-backed initiatives to promote digital health integration, supports this evolution. For instance, BeMedTech, the Belgian federation representing the medical technology industry, has been actively promoting AI-powered healthcare solutions to improve patient outcomes. Furthermore, medical device manufacturers are investing in AI-powered platforms that integrate seamlessly with electronic health records (EHRs) and telecardiology systems, enabling a more connected and efficient healthcare environment. As a result, the convergence of AI and cardiovascular care is driving operational efficiency, improving clinical outcomes, and opening new revenue streams for device manufacturers in the Belgian market.

Rising Popularity of Wearable and Ambulatory Monitoring Devices

Wearable technology and ambulatory monitoring devices are gaining substantial traction in the Belgium cardiovascular devices market. As patients seek more autonomy and continuous monitoring for chronic heart conditions, devices such as smartwatches with ECG functions, Holter monitors, and mobile cardiac telemetry systems are becoming mainstream. These tools enable real-time tracking of heart rhythms, blood pressure, and other vital metrics, allowing early detection of arrhythmias and ischemic events. Belgian healthcare providers are leveraging these devices to shift parts of patient management from hospital settings to home-based care, reducing the strain on clinical resources and enhancing patient comfort. Moreover, the demand is further propelled by Belgium’s growing elderly population and increased incidence of chronic cardiovascular disorders. Reimbursement support for remote monitoring, along with patient education initiatives by hospitals and NGOs, is encouraging widespread adoption. Manufacturers are responding by designing lightweight, user-friendly, and clinically validated wearable solutions that seamlessly sync with smartphones and cloud platforms. This trend reflects a broader shift toward preventive and personalized healthcare, where wearable cardiac monitoring devices act as critical tools for long-term disease management, fostering both improved outcomes and market expansion.

Strategic Collaborations and R\&D Investments by Global Players

Strategic collaborations between global medical device companies and local healthcare institutions are driving innovation and competitive growth in Belgium’s cardiovascular devices market. Multinational players such as Medtronic, Abbott, Boston Scientific, and Philips are forming partnerships with Belgian hospitals, universities, and research centers to co-develop and pilot new cardiovascular technologies. These collaborations support clinical trials, device validation, and physician training programs, accelerating the market entry of cutting-edge products. Belgium’s favorable regulatory environment and reputation as a leading hub for clinical research in Europe attract substantial foreign direct investment in the healthcare sector. Moreover, companies are increasing R\&D spending to tailor their products to local market needs, including devices for treating complex and comorbid cardiac conditions common among Belgium’s aging population. Joint ventures and technology licensing agreements are also enabling faster innovation cycles and knowledge transfer. Start-ups and academic spin-offs in Belgium are contributing to this dynamic ecosystem by developing AI-based cardiac diagnostics, bioresorbable stents, and next-generation pacemakers. These strategic moves not only enhance the availability of innovative cardiovascular solutions but also strengthen Belgium’s position as a key player in the European cardiovascular device landscape.

Market Challenges

High Cost of Advanced Cardiovascular Devices and Procedures

One of the primary challenges facing the Belgium cardiovascular devices market is the high cost associated with advanced technologies and minimally invasive procedures. Although Belgium offers universal healthcare coverage, many next-generation cardiovascular devices—such as leadless pacemakers, drug-eluting stents, and transcatheter valve systems—come with a substantial price tag. These high costs can strain hospital budgets, especially in public healthcare institutions that operate under strict reimbursement frameworks. While reimbursement policies do exist for many essential cardiac procedures, they often lag behind technological advancements, leading to delays in the adoption of novel devices. Smaller clinics and rural hospitals may also face difficulties in acquiring the capital-intensive infrastructure required for advanced interventional procedures, such as hybrid operating rooms or robotic-assisted systems. For instance, hospitals in Belgium have reported challenges in integrating robotic-assisted surgical systems due to high acquisition and maintenance costs. Furthermore, the cost burden is not limited to procurement but extends to training, maintenance, and post-operative care. These financial constraints can hinder widespread access to cutting-edge cardiovascular treatments, thereby impacting equitable healthcare delivery. As cost-effectiveness becomes a growing priority for Belgian healthcare decision-makers, manufacturers must demonstrate clear clinical and economic value to support market penetration of high-cost devices. Without broader financial support and streamlined reimbursement approvals, the pace of innovation adoption may slow, limiting market expansion and patient outcomes.

Regulatory Complexity and Lengthy Product Approval Timelines

Another significant challenge in the Belgium cardiovascular devices market stems from the increasingly complex regulatory landscape, particularly in the wake of the European Union’s Medical Device Regulation (EU MDR). While these regulations aim to enhance patient safety and product quality, they also impose more stringent requirements on clinical evaluation, documentation, and post-market surveillance. Manufacturers now face longer timelines and higher costs to bring new cardiovascular devices to market. This complexity can especially burden small and medium-sized enterprises (SMEs), which often lack the internal resources to manage extensive compliance requirements. Additionally, delays in product approvals may lead to slower innovation cycles and reduced competitive agility, hindering Belgium’s position as a frontrunner in medical technology adoption.

Market Opportunities

Expansion of Home-Based and Remote Cardiac Monitoring Solutions

The growing emphasis on preventive care and chronic disease management presents a substantial opportunity for expanding home-based and remote cardiac monitoring solutions in Belgium. With an aging population and increasing prevalence of long-term cardiovascular conditions, there is a strong demand for technologies that support continuous monitoring beyond clinical settings. Wearable ECG monitors, mobile telemetry systems, and smartphone-integrated diagnostic tools are gaining traction as they enable early detection of anomalies and reduce the need for frequent hospital visits. Belgium’s well-established digital infrastructure and the adoption of telehealth during the COVID-19 pandemic have laid the groundwork for long-term integration of these solutions. Furthermore, ongoing efforts by healthcare providers and insurers to support decentralized care models through reimbursement policies could unlock greater market potential for remote monitoring devices, benefiting both patients and healthcare systems.

Increasing Demand for Personalized and AI-Driven Cardiovascular Solutions

The shift toward personalized medicine and precision cardiology offers a high-growth opportunity for device manufacturers in Belgium. Advanced analytics, AI-powered diagnostic tools, and machine learning algorithms are increasingly being utilized to tailor treatments based on individual patient profiles. This trend is supported by Belgium’s active involvement in clinical research and its robust data-sharing frameworks across hospitals and academic centers. Medical device companies can capitalize on this ecosystem by introducing intelligent cardiovascular devices that integrate with electronic health records and predictive analytics platforms. Such innovations not only improve clinical outcomes but also position manufacturers at the forefront of next-generation cardiovascular care.

Market Segmentation Analysis

By Product

The Belgium cardiovascular devices market is segmented into diagnostic & monitoring devices and surgical devices. Diagnostic and monitoring devices, which include electrocardiogram (ECG) systems, Holter monitors, cardiac event monitors, and echocardiography equipment, hold a significant share due to their widespread use in early disease detection, routine cardiac screening, and long-term patient monitoring. Increasing awareness of preventive care and the growing burden of cardiovascular conditions have elevated demand for non-invasive diagnostic tools across hospitals and outpatient settings. Meanwhile, the surgical devices segment—comprising stents, catheters, pacemakers, implantable cardioverter defibrillators (ICDs), and cardiac assist devices—is expected to witness robust growth. The surge in minimally invasive and image-guided procedures, combined with advancements in device durability and efficacy, is encouraging Belgian cardiologists to adopt modern surgical solutions, particularly in tertiary care facilities.

By End User

Hospitals and clinics dominate the end-user segment in Belgium, driven by their capacity to handle a high volume of complex cardiovascular procedures and advanced diagnostics. These facilities are equipped with state-of-the-art infrastructure and skilled healthcare professionals, making them the primary hub for cardiovascular treatments and interventions. Diagnostic laboratories also play a vital role in the market by supporting routine and preventive cardiovascular testing, particularly in urban centers where early screening is emphasized. Ambulatory surgical centers are emerging as a cost-effective and efficient alternative for less complex interventions and outpatient procedures, reflecting the healthcare sector’s shift toward decentralized care models. The “Others” category, which includes specialty cardiac centers and research institutions, continues to contribute to innovation and niche services in the cardiovascular care spectrum.

Segments

Based on Product

Diagnostic & Monitoring Devices
Surgical Devices

Based on End User

Hospitals & Clinics
Diagnostic Laboratories
Ambulatory Surgical Centers
Others

Based on Diagnostic & Monitoring Devices Type

ECG
Implantable Cardiac Monitors
Holter Monitors
Mobile Cardiac Telemetry
MRI
Others

Based on Surgical Devices Type

Cardiac Resynchronization Therapy (CRT)
Implantable Cardioverter Defibrillators (ICDs
Pacemakers
Coronary Stents
Catheters

Based on Region

Flanders
Wallonia
Brussels-Capital

Regional Analysis

Flanders (48%)

Flanders holds the largest share of the Belgium cardiovascular devices market, accounting for approximately 48% of the national market. This dominance is primarily attributed to its dense population, higher concentration of tertiary care hospitals, and extensive network of diagnostic laboratories. Cities like Antwerp, Ghent, and Leuven are home to leading academic hospitals and medical research institutions, which have been early adopters of advanced cardiovascular technologies such as robotic-assisted surgical systems, AI-powered diagnostics, and minimally invasive catheterization procedures. The presence of a skilled healthcare workforce and public-private collaboration in healthcare innovation further strengthen the region’s position in the market.

Wallonia (32%)

Wallonia represents around 32% of the market share, supported by ongoing investments in hospital modernization and expansion of cardiovascular services in both urban and semi-urban areas. Although traditionally considered slower in adopting high-end medical technologies, Wallonia is experiencing steady growth as healthcare providers increasingly prioritize early detection and preventive cardiac care. Government initiatives to enhance healthcare accessibility and infrastructure in underserved areas have helped improve patient outcomes, thereby creating a favorable environment for cardiovascular device penetration. Cities like Liège and Namur are emerging as important regional hubs for cardiac diagnostics and interventions.

Key players

Abbott
GE HealthCare
Edwards Lifesciences Corporation
L. Gore & Associates, Inc.
Siemens Healthcare GmbH
BIOTRONIK SE & Co. KG
Canon Medical Systems Asia Pte. Ltd.
Cardinal Health
Medtronic
Boston Scientific Corporation
Johnson & Johnson Services, Inc.
LivaNova
UCB
Elekta
ThromboGenics (now part of Biocartis)

Competitive Analysis

The Belgium cardiovascular devices market is highly competitive and features a mix of global medtech giants and regionally influential players. Companies like Abbott, Medtronic, and Boston Scientific lead the market due to their expansive cardiovascular portfolios, continuous product innovation, and robust distribution networks. These firms invest heavily in R\&D and collaborate with Belgian hospitals to pilot next-generation technologies such as leadless pacemakers, AI-powered diagnostics, and transcatheter therapies. GE HealthCare, Siemens, and Canon Medical Systems dominate the imaging and diagnostics segment with cutting-edge echocardiography and cardiac MRI systems. Meanwhile, niche innovators like Edwards Lifesciences and LivaNova specialize in structural heart devices and advanced cardiac surgery solutions. Domestic players like UCB and Biocartis contribute to research and personalized healthcare innovation. Overall, the competitive landscape is driven by technology integration, strategic partnerships, and a strong emphasis on personalized cardiovascular care.

Recent Developments

In February 2025, Abbott issued a safety notification for certain Assurity and Endurity pacemakers due to potential epoxy mixing issues during manufacturing, which could lead to device malfunction.

In April 2025, GE HealthCare launched the Revolution™ Vibe CT system featuring Unlimited One-Beat Cardiac imaging and AI solutions, enhancing cardiac imaging capabilities.

In April 2025, Medtronic reported promising evidence for its Affera™ pulsed field ablation technologies in treating atrial fibrillation patients.

In May 2024, Siemens Healthineers announced new cardiology applications with artificial intelligence for the Acuson Sequoia ultrasound system, including a new 4D transesophageal (TEE) transducer for cardiology exams.

In February 2025, Philips developed a miniaturized intracardiac transducer, enabling higher-resolution views of cardiac structures and functions, benefiting structural heart disease and electrophysiology procedures.

In March 2025, Boston Scientific announced the acquisition of SoniVie Ltd. to expand its interventional cardiology therapies offerings with ultrasound-based renal denervation technology.

In June 2024, Biovac Institute entered a partnership with Sanofi to locally manufacture inactivated polio vaccines in Africa, aiming to serve the potential needs of over 40 African countries.

Market Concentration and Characteristics

The Belgium cardiovascular devices market exhibits a moderate to high level of market concentration, dominated by a few global players such as Abbott, Medtronic, Boston Scientific, and GE HealthCare, who collectively hold a significant share due to their comprehensive product portfolios and strong distribution networks. These multinational companies benefit from well-established relationships with leading Belgian hospitals and research institutions, allowing early adoption of advanced technologies. The market is characterized by a growing demand for minimally invasive procedures, AI-integrated diagnostics, and home-based monitoring solutions, reflecting a shift toward preventive and personalized care. Additionally, the market demonstrates strong regulatory compliance with EU medical device standards, high healthcare expenditure per capita, and a technologically advanced clinical environment. While innovation is largely driven by foreign firms, Belgium’s supportive healthcare infrastructure and active clinical research ecosystem foster opportunities for localized partnerships and niche product development.

Report Coverage

The research report offers an in-depth analysis based on Product, End User, Diagnostic & Monitoring Devices Type, Surgical Devices Type and Region. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market

Future Outlook

The Belgium cardiovascular devices market is expected to maintain steady growth, driven by rising incidences of chronic heart diseases and an aging population demanding advanced treatment options.

Ongoing advancements in minimally invasive surgical technologies will enhance procedural efficiency and increase patient preference for non-invasive interventions.

Integration of artificial intelligence and machine learning in cardiac diagnostics is projected to streamline early disease detection and improve personalized treatment plans.

Wearable and portable cardiac monitoring devices will see increased adoption as remote healthcare and home-based monitoring become standard components of chronic care.

The expansion of telecardiology services across urban and rural regions will improve accessibility to specialized cardiovascular care and reduce hospital dependency.

Favorable government policies, reimbursement frameworks, and EU-aligned regulatory standards will continue to support the rapid approval and adoption of innovative devices.

Strategic collaborations between multinational firms and Belgian healthcare institutions will foster clinical research, accelerate product validation, and strengthen local market penetration.

Increased focus on preventive healthcare and patient education will drive demand for diagnostic devices and early screening technologies, enhancing disease management outcomes.

Start-ups and academic spin-offs in Belgium are expected to contribute more actively to cardiovascular innovation through AI-driven diagnostics and device development.

As healthcare providers embrace data-driven care models, cardiovascular devices with integrated analytics and EHR compatibility will gain significant market traction.

CHAPTER NO. 1 : INTRODUCTION 17

1.1.1. Report Description 17

Purpose of the Report 17

USP & Key Product 17

1.1.2. Key Benefits for Stakeholders 17

1.1.3. Target Audience 18

1.1.4. Report Scope 18

CHAPTER NO. 2 : EXECUTIVE SUMMARY 19

2.1. Cardiovascular Devices Market Snapshot 19

2.1.1. Belgium Cardiovascular Devices Market, 2018 – 2032 (USD Million) 20

CHAPTER NO. 3 : GEOPOLITICAL CRISIS IMPACT ANALYSIS 21

3.1. Russia-Ukraine and Israel-Palestine War Impacts 21

CHAPTER NO. 4 : CARDIOVASCULAR DEVICES MARKET – INDUSTRY ANALYSIS 22

4.1. Introduction 22

4.2. Market Drivers 23

4.2.1. Driving Factor 1 Analysis 23

4.2.2. Driving Factor 2 Analysis 24

4.3. Market Restraints 25

4.3.1. Restraining Factor Analysis 25

4.4. Market Opportunities 26

4.4.1. Market Opportunities Analysis 26

4.5. Porter’s Five Force analysis 27

4.6. Value Chain Analysis 28

4.7. Buying Criteria 29

CHAPTER NO. 5 : ANALYSIS COMPETITIVE LANDSCAPE 30

5.1. Company Market Share Analysis – 2023 30

5.1.1. Belgium Cardiovascular Devices Market: Company Market Share, by Revenue, 2023 30

5.1.2. Belgium Cardiovascular Devices Market: Top 6 Company Market Share, by Revenue, 2023 30

5.1.3. Belgium Cardiovascular Devices Market: Top 3 Company Market Share, by Revenue, 2023 31

5.2. Belgium Cardiovascular Devices Market Company Revenue Market Share, 2023 32

5.3. Company Assessment Metrics, 2023 33

5.3.1. Stars 33

5.3.2. Emerging Leaders 33

5.3.3. Pervasive Players 33

5.3.4. Participants 33

5.4. Start-ups /Code Assessment Metrics, 2023 33

5.4.1. Progressive Companies 33

5.4.2. Responsive Companies 33

5.4.3. Dynamic Companies 33

5.4.4. Starting Blocks 33

5.5. Strategic Developments 34

5.5.1. Acquisition & Mergers 34

New Product Launch 34

Regional Expansion 34

5.6. Key Players Product Matrix 35

CHAPTER NO. 6 : PESTEL & ADJACENT MARKET ANALYSIS 36

6.1. PESTEL 36

6.1.1. Political Factors 36

6.1.2. Economic Factors 36

6.1.3. Social Factors 36

6.1.4. Technological Factors 36

6.1.5. Environmental Factors 36

6.1.6. Legal Factors 36

6.2. Adjacent Market Analysis 36

CHAPTER NO. 7 : CARDIOVASCULAR DEVICES MARKET – BY PRODUCT SEGMENT ANALYSIS 37

7.1. Cardiovascular Devices Market Overview, by Product Segment 37

7.1.1. Cardiovascular Devices Market Revenue Share, By Product, 2023 & 2032 38

7.1.2. Cardiovascular Devices Market Attractiveness Analysis, By Product 39

7.1.3. Incremental Revenue Growth Opportunities, by Product, 2024 – 2032 39

7.1.4. Cardiovascular Devices Market Revenue, By Product, 2018, 2023, 2027 & 2032 40

7.2. Diagnostic & Monitoring Devices 41

7.2.1. Belgium Cardiovascular Devices Market Revenue, By Diagnostic & Monitoring Device Types, 2018 – 2023 (USD Million) 42

7.3. Surgical Devices 43

7.3.1. Belgium Cardiovascular Devices Market Revenue, By Surgical Devices Types, 2018 – 2023 (USD Million) 44

7.3.2. Belgium Cardiovascular Devices Market Revenue, By Surgical Devices Types, 2018 – 2023 (USD Million) 44

CHAPTER NO. 8 : CARDIOVASCULAR DEVICES MARKET – BY END USER SEGMENT ANALYSIS 45

8.1. Cardiovascular Devices Market Overview, by End User Segment 45

8.1.1. Cardiovascular Devices Market Revenue Share, By End User, 2023 & 2032 46

8.1.2. Cardiovascular Devices Market Attractiveness Analysis, By End User 47

8.1.3. Incremental Revenue Growth Opportunities, by End User, 2024 – 2032 47

8.1.4. Cardiovascular Devices Market Revenue, By End User, 2018, 2023, 2027 & 2032 48

8.2. Hospitals & Clinics 49

8.3. Diagnostic Laboratories 50

8.4. Ambulatory Surgical Centers 51

8.5. Others 52

CHAPTER NO. 9 : CARDIOVASCULAR DEVICES MARKET – BELGIUM 53

9.1. Belgium 53

9.1.1. Key Highlights 53

9.1.2. Belgium Cardiovascular Devices Market Revenue, By Country, 2018 – 2023 (USD Million) 54

9.2. Product 55

9.3. Belgium Cardiovascular Devices Market Revenue, By Product, 2018 – 2023 (USD Million) 55

9.4. Belgium Cardiovascular Devices Market Revenue, By Product, 2024 – 2032 (USD Million) 55

9.5. Diagnostic & Monitoring Device Types 56

9.5.1. Belgium Cardiovascular Devices Market Revenue, By Diagnostic & Monitoring Device Types, 2018 – 2023 (USD Million) 56

9.5.2. Belgium Cardiovascular Devices Market Revenue, By Diagnostic & Monitoring Device Types, 2018 – 2023 (USD Million) 56

9.6. Surgical Devices Types 57

9.6.1. Belgium Cardiovascular Devices Market Revenue, By Surgical Devices Types, 2018 – 2023 (USD Million) 57

9.6.2. Belgium Cardiovascular Devices Market Revenue, By Surgical Devices Types, 2018 – 2023 (USD Million) 57

9.7. End User 58

9.7.1. Belgium Cardiovascular Devices Market Revenue, By End User, 2018 – 2023 (USD Million) 58

9.7.2. Belgium Cardiovascular Devices Market Revenue, By End User, 2024 – 2032 (USD Million) 58

CHAPTER NO. 10 : COMPANY PROFILES 59

10.1. Abbott 59

10.1.1. Company Overview 59

10.1.2. Product Portfolio 59

10.1.3. Swot Analysis 59

10.1.4. Business Strategy 60

10.1.5. Financial Overview 60

10.2. GE HealthCare 61

10.3. Edwards Lifesciences Corporation 61

10.4. W. L. Gore & Associates, Inc. 61

10.5. Siemens Healthcare GmbH 61

10.6. BIOTRONIK SE & Co. KG 61

10.7. Canon Medical Systems Asia Pte. Ltd. 61

10.8. Cardinal Health 61

10.9. Medtronic 61

10.10. Boston Scientific Corporation 61

10.11. Johnson & Johnson Services, Inc 61

10.12. LivaNova 61

10.13. UCB 61

10.14. Elekta 61

10.15. ThromboGenics (now part of Biocartis) 61

10.16. Others 61

]

List of Figures

FIG NO. 1. Belgium Cardiovascular Devices Market Revenue, 2018 – 2032 (USD Million) 20

FIG NO. 2. Porter’s Five Forces Analysis for Belgium Cardiovascular Devices Market 27

FIG NO. 3. Value Chain Analysis for Belgium Cardiovascular Devices Market 28

FIG NO. 4. Company Share Analysis, 2023 30

FIG NO. 5. Company Share Analysis, 2023 30

FIG NO. 6. Company Share Analysis, 2023 31

FIG NO. 7. Cardiovascular Devices Market – Company Revenue Market Share, 2023 32

FIG NO. 8. Cardiovascular Devices Market Revenue Share, By Product, 2023 & 2032 38

FIG NO. 9. Market Attractiveness Analysis, By Product 39

FIG NO. 10. Incremental Revenue Growth Opportunities by Product, 2024 – 2032 39

FIG NO. 11. Cardiovascular Devices Market Revenue, By Product, 2018, 2023, 2027 & 2032 40

FIG NO. 12. Belgium Cardiovascular Devices Market for Diagnostic & Monitoring Devices, Revenue (USD Million) 2018 – 2032 41

FIG NO. 13. Belgium Cardiovascular Devices Market for Surgical Devices, Revenue (USD Million) 2018 – 2032 43

FIG NO. 14. Cardiovascular Devices Market Revenue Share, By End User, 2023 & 2032 46

FIG NO. 15. Market Attractiveness Analysis, By End User 47

FIG NO. 16. Incremental Revenue Growth Opportunities by End User, 2024 – 2032 47

FIG NO. 17. Cardiovascular Devices Market Revenue, By End User, 2018, 2023, 2027 & 2032 48

FIG NO. 18. Belgium Cardiovascular Devices Market for Hospitals & Clinics, Revenue (USD Million) 2018 – 2032 49

FIG NO. 19. Belgium Cardiovascular Devices Market for Diagnostic Laboratories, Revenue (USD Million) 2018 – 2032 50

FIG NO. 20. Belgium Cardiovascular Devices Market for Ambulatory Surgical Centers, Revenue (USD Million) 2018 – 2032 51

FIG NO. 21. Belgium Cardiovascular Devices Market for Others, Revenue (USD Million) 2018 – 2032 52

FIG NO. 22. Belgium Cardiovascular Devices Market Revenue, 2018 – 2032 (USD Million) 53

List of Tables

TABLE NO. 1. : Belgium Cardiovascular Devices Market: Snapshot 19

TABLE NO. 2. : Drivers for the Cardiovascular Devices Market: Impact Analysis 23

TABLE NO. 3. : Restraints for the Cardiovascular Devices Market: Impact Analysis 25

TABLE NO. 4. : Belgium Cardiovascular Devices Market Revenue, By Diagnostic & Monitoring Device Types, 2018 – 2023 (USD Million) 42

TABLE NO. 5. : Belgium Cardiovascular Devices Market Revenue, By Diagnostic & Monitoring Device Types, 2018 – 2023 (USD Million) 42

TABLE NO. 6. : Belgium Cardiovascular Devices Market Revenue, By Surgical Devices Types, 2018 – 2023 (USD Million) 44

TABLE NO. 7. : Belgium Cardiovascular Devices Market Revenue, By Surgical Devices Types, 2018 – 2023 (USD Million) 44

TABLE NO. 8. : Belgium Cardiovascular Devices Market Revenue, By Country, 2018 – 2023 (USD Million) 54

TABLE NO. 9. : Belgium Cardiovascular Devices Market Revenue, By Country, 2024 – 2032 (USD Million) 54

TABLE NO. 10. : Belgium Cardiovascular Devices Market Revenue, By Product, 2018 – 2023 (USD Million) 55

TABLE NO. 11. : Belgium Cardiovascular Devices Market Revenue, By Product, 2024 – 2032 (USD Million) 55

TABLE NO. 12. : Belgium Cardiovascular Devices Market Revenue, By Diagnostic & Monitoring Device Types, 2018 – 2023 (USD Million) 56

TABLE NO. 13. : Belgium Cardiovascular Devices Market Revenue, By Diagnostic & Monitoring Device Types, 2018 – 2023 (USD Million) 56

TABLE NO. 14. : Belgium Cardiovascular Devices Market Revenue, By Surgical Devices Types, 2018 – 2023 (USD Million) 57

TABLE NO. 15. : Belgium Cardiovascular Devices Market Revenue, By Surgical Devices Types, 2018 – 2023 (USD Million) 57

TABLE NO. 16. : Belgium Cardiovascular Devices Market Revenue, By End User, 2018 – 2023 (USD Million) 58

TABLE NO. 17. : Belgium Cardiovascular Devices Market Revenue, By End User, 2024 – 2032 (USD Million) 58

Frequently Asked Questions

What was the market size of the Belgium Cardiovascular Devices Market in 2023, and what is its projected size by 2032?

The market was valued at USD449.08 million in 2024 and is expected to reach USD706.83 million by 2032, growing at a CAGR of 5.2% from 2025 to 2032. The 2023 market size is slightly lower, reflecting consistent annual growth.

What factors are driving the growth of the cardiovascular devices market in Belgium?

Rising cardiovascular disease prevalence, increasing healthcare spending, and the adoption of advanced technologies are key factors fueling market growth in Belgium.

Which cardiovascular device types are in high demand in the Belgian market?

Devices such as diagnostic imaging systems, interventional tools, cardiac rhythm management devices, and minimally invasive surgical instruments are in strong demand.

Who are the major players in the Belgium cardiovascular devices market?

Leading companies include Medtronic, Abbott, Boston Scientific, GE HealthCare, Siemens Healthineers, and Philips Healthcare, all of which invest heavily in innovation and local partnerships.

Purchase Options

Single User

$2699

Multi User

$3699

Custom Report

$5699

Let us help you

MIKE, North America

+1 304 308 1216

KEITH PHILLIPS, Europe

+44 7809 866 263

EMAIL US

Request Sample

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –